This HTML5 document contains 80 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://linked.opendata.cz/resource/drugbank/drug/DB04861/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB04861/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB04861/identifier/drugbank/
n11http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB04861/identifier/national-drug-code-directory/
n16http://www.rxlist.com/
n15http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB04861/identifier/chemspider/
n10http://www.pdrhealth.com/drugs/rx/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04861/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB04861/identifier/pharmgkb/
n13http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB04861/identifier/pubchem-compound/
n29http://linked.opendata.cz/resource/atc/
n28http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04861
rdf:type
n3:Drug
n3:description
Nebivolol is a highly cardioselective vasodilatory beta1 receptor blocker used in treatment of hypertension. In most countries, this medication is available only by prescription. [Wikipedia]
n3:dosage
n8:271B5A98-363D-11E5-9242-09173F13E4C5 n8:271B5A99-363D-11E5-9242-09173F13E4C5 n8:271B5A9A-363D-11E5-9242-09173F13E4C5 n8:271B5A9B-363D-11E5-9242-09173F13E4C5 n8:271B5A95-363D-11E5-9242-09173F13E4C5 n8:271B5A96-363D-11E5-9242-09173F13E4C5 n8:271B5A97-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16961165
n3:group
investigational approved
n3:halfLife
10 hours
n3:indication
For the treatment of essential hypertension.
owl:sameAs
n15:DB04861 n17:DB04861
dcterms:title
Nebivolol
adms:identifier
n6:Nebivolol n21:64421 n22:54868-5944-0 n23:PA151958426 n24:DB04861 n25:D05127 n26:71301 n27:99443225
n3:mechanismOfAction
Nebivolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors.
n3:packager
n11:271B5A8D-363D-11E5-9242-09173F13E4C5 n11:271B5A8E-363D-11E5-9242-09173F13E4C5 n11:271B5A8F-363D-11E5-9242-09173F13E4C5 n11:271B5A90-363D-11E5-9242-09173F13E4C5
n3:patent
n12:5759580 n12:6545040
n3:synonym
alpha,Alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol) 1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol alpha,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol) 1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol Nebivololum
n3:toxicity
The most common signs and symptoms associated with nebivolol overdosage are bradycardia and hypotension. Other important adverse events reported with nebivolol overdose include cardiac failure, dizziness, hypoglycemia, fatigue and vomiting. Other adverse events associated with β-blocker overdose include bronchospasm and heart block. The largest known ingestion of nebivolol worldwide involved a patient who ingested up to 500 mg of nebivolol along with several 100 mg tablets of acetylsalicylic acid in a suicide attempt. The patient experienced hyperhydrosis, pallor, depressed level of consciousness, hypokinesia, hypotension, sinus bradycardia, hypoglycemia, hypokalemia, respiratory failure and vomiting. The patient recovered.
n3:proteinBinding
98%
n3:salt
n3:synthesisReference
Thomas Bader, Alfred Stutz, Harald Hofmeier, Hans-Ulrich Bichsel, "Process for preparation of racemic Nebivolol." U.S. Patent US20070149612, issued June 28, 2007.
n19:hasConcept
n20:M0149652
foaf:page
n10:rx-mono.aspx?contentFileName=bys1940.html&contentName=Bystolic&contentId=732 n13:nebivolol.html n16:bystolic-tablets-drug.htm
n3:IUPAC-Name
n4:271B5AA0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5AA6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5AA5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5AA2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5AA3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5AA4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5A9E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5A9F-363D-11E5-9242-09173F13E4C5 n4:271B5A9C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5A9D-363D-11E5-9242-09173F13E4C5
n28:hasATCCode
n29:C07AB12
n3:H-Bond-Acceptor-Count
n4:271B5AAC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5AAD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5AA7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5AA8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5AAA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5AA9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5AAB-363D-11E5-9242-09173F13E4C5
n3:absorption
The absorption of nebivolol is rapid and not affected by food.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
99200-09-6
n3:category
n3:containedIn
n7:271B5A94-363D-11E5-9242-09173F13E4C5 n7:271B5A92-363D-11E5-9242-09173F13E4C5 n7:271B5A93-363D-11E5-9242-09173F13E4C5 n7:271B5A91-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5AB2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5AB4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5AB5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5AB1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5AB0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5AB3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5AA1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5AAE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5AAF-363D-11E5-9242-09173F13E4C5